' 
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: 2 Capsules
Amount Per Serving
%DV
Total Carbohydrate
<1g
<1%†
Calcium (from calcium magnesium phytate)
131 mg
10%
Phosphorus (from calcium magnesium phytate)
192 mg
15%
Magnesium (from calcium magnesium phytate)
40 mg
10%
IP-6 (inositol hexaphosphate) (from calcium magnesium phytate)
800 mg
**
Inositol
220 mg
**
Maitake Mushroom Extract standardized to 30% pure D-fraction (9 mg)
30 mg
**
Cat's Claw Extract (bark) standardized to 4% alkaloids (0.4 mg)
10 mg
**
Top Medical Research Studies
8
SNF472 shows promise for ulcers
Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis.
Direct evaluation of SNF472
We explored the effects of SNF472, an intravenous treatment derived from myo-inositol hexaphosphate, on patients suffering from calciphylaxis, a condition often marked by painful, necrotic skin ulcers. Our study involved fourteen patients who were already receiving standard care and thrice-weekly hemodialysis. Over a 12-week period, these patients received SNF472 three times a week, allowing us to assess its potential benefits on wound healing, pain relief, and overall quality of life.
Assessments used included the Bates-Jensen Wound Assessment Tool for measuring wound healing, a visual analog scale for pain, and a specific quality of life questionnaire focused on wound healing. The results were promising: we observed significant improvements in wound healing, with reductions in pain and enhancements in quality of life. Notably, more than half of the patients who started with ulcerated lesions showed an improvement by the end of the study.
The treatment was well tolerated, with no serious adverse events directly linked to SNF472. Most side effects were typical for hemodialysis patients and were not considered treatment-related. These positive findings suggest that SNF472 could be a viable new option for managing the challenging symptoms of calciphylaxis, paving the way for future randomized trials to confirm its efficacy.
Assessments used included the Bates-Jensen Wound Assessment Tool for measuring wound healing, a visual analog scale for pain, and a specific quality of life questionnaire focused on wound healing. The results were promising: we observed significant improvements in wound healing, with reductions in pain and enhancements in quality of life. Notably, more than half of the patients who started with ulcerated lesions showed an improvement by the end of the study.
The treatment was well tolerated, with no serious adverse events directly linked to SNF472. Most side effects were typical for hemodialysis patients and were not considered treatment-related. These positive findings suggest that SNF472 could be a viable new option for managing the challenging symptoms of calciphylaxis, paving the way for future randomized trials to confirm its efficacy.
Read More
8
Quebrachitol shows ulcer protection
Quebrachitol-induced gastroprotection against acute gastric lesions: role of prostaglandins, nitric oxide and K+ ATP channels.
Relevant study on gastric injury
We explored the impact of Quebrachitol, a natural compound derived from the fruit of Magonia glabrata, on stomach ulcers caused by absolute ethanol and indomethacin in mice. The research involved administering various doses of Quebrachitol to determine how effective it could be in reducing gastric lesions.
Interestingly, we found that Quebrachitol significantly reduced the severity of these lesions. At doses of 12.5, 25, and 50 mg/kg, it helped to lessen the damage from ethanol by 69%, 64%, and 53%, respectively. Similarly, it showed protective effects against indomethacin-induced lesions, with reductions of 55%, 59%, and 26%.
We noticed that the gastroprotective effects of Quebrachitol were influenced by several factors, including the body's own production of prostaglandins and nitric oxide. However, when we blocked these mechanisms or inhibited the potassium ATP (K+ ATP) channels, the protective effect appeared to diminish, indicating these pathways play a crucial role in its effectiveness.
Overall, this research provides promising evidence that Quebrachitol could help combat gastric damage from various substances. Its benefits seem to stem from its ability to promote the release of natural protective substances in our body.
Interestingly, we found that Quebrachitol significantly reduced the severity of these lesions. At doses of 12.5, 25, and 50 mg/kg, it helped to lessen the damage from ethanol by 69%, 64%, and 53%, respectively. Similarly, it showed protective effects against indomethacin-induced lesions, with reductions of 55%, 59%, and 26%.
We noticed that the gastroprotective effects of Quebrachitol were influenced by several factors, including the body's own production of prostaglandins and nitric oxide. However, when we blocked these mechanisms or inhibited the potassium ATP (K+ ATP) channels, the protective effect appeared to diminish, indicating these pathways play a crucial role in its effectiveness.
Overall, this research provides promising evidence that Quebrachitol could help combat gastric damage from various substances. Its benefits seem to stem from its ability to promote the release of natural protective substances in our body.
Read More
Most Useful Reviews
8
Supports healing process
Although my Bullmastiff has lymphoma, he experiences no pain. I've been giving him this product for about a year to assist with healing his occasional skin ulcers on his feet, and increasing the dosage has proven effective. I believe this product has significantly contributed to his well-being and survival despite his diagnosis.
Read More
Most Recommended Products for Ulcer
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8
- All Researches
8
SNF472 shows promise for ulcers
Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis.
Direct evaluation of SNF472
We explored the effects of SNF472, an intravenous treatment derived from myo-inositol hexaphosphate, on patients suffering from calciphylaxis, a condition often marked by painful, necrotic skin ulcers. Our study involved fourteen patients who were already receiving standard care and thrice-weekly hemodialysis. Over a 12-week period, these patients received SNF472 three times a week, allowing us to assess its potential benefits on wound healing, pain relief, and overall quality of life.
Assessments used included the Bates-Jensen Wound Assessment Tool for measuring wound healing, a visual analog scale for pain, and a specific quality of life questionnaire focused on wound healing. The results were promising: we observed significant improvements in wound healing, with reductions in pain and enhancements in quality of life. Notably, more than half of the patients who started with ulcerated lesions showed an improvement by the end of the study.
The treatment was well tolerated, with no serious adverse events directly linked to SNF472. Most side effects were typical for hemodialysis patients and were not considered treatment-related. These positive findings suggest that SNF472 could be a viable new option for managing the challenging symptoms of calciphylaxis, paving the way for future randomized trials to confirm its efficacy.
Assessments used included the Bates-Jensen Wound Assessment Tool for measuring wound healing, a visual analog scale for pain, and a specific quality of life questionnaire focused on wound healing. The results were promising: we observed significant improvements in wound healing, with reductions in pain and enhancements in quality of life. Notably, more than half of the patients who started with ulcerated lesions showed an improvement by the end of the study.
The treatment was well tolerated, with no serious adverse events directly linked to SNF472. Most side effects were typical for hemodialysis patients and were not considered treatment-related. These positive findings suggest that SNF472 could be a viable new option for managing the challenging symptoms of calciphylaxis, paving the way for future randomized trials to confirm its efficacy.
Read More
8
Quebrachitol shows ulcer protection
Quebrachitol-induced gastroprotection against acute gastric lesions: role of prostaglandins, nitric oxide and K+ ATP channels.
Relevant study on gastric injury
We explored the impact of Quebrachitol, a natural compound derived from the fruit of Magonia glabrata, on stomach ulcers caused by absolute ethanol and indomethacin in mice. The research involved administering various doses of Quebrachitol to determine how effective it could be in reducing gastric lesions.
Interestingly, we found that Quebrachitol significantly reduced the severity of these lesions. At doses of 12.5, 25, and 50 mg/kg, it helped to lessen the damage from ethanol by 69%, 64%, and 53%, respectively. Similarly, it showed protective effects against indomethacin-induced lesions, with reductions of 55%, 59%, and 26%.
We noticed that the gastroprotective effects of Quebrachitol were influenced by several factors, including the body's own production of prostaglandins and nitric oxide. However, when we blocked these mechanisms or inhibited the potassium ATP (K+ ATP) channels, the protective effect appeared to diminish, indicating these pathways play a crucial role in its effectiveness.
Overall, this research provides promising evidence that Quebrachitol could help combat gastric damage from various substances. Its benefits seem to stem from its ability to promote the release of natural protective substances in our body.
Interestingly, we found that Quebrachitol significantly reduced the severity of these lesions. At doses of 12.5, 25, and 50 mg/kg, it helped to lessen the damage from ethanol by 69%, 64%, and 53%, respectively. Similarly, it showed protective effects against indomethacin-induced lesions, with reductions of 55%, 59%, and 26%.
We noticed that the gastroprotective effects of Quebrachitol were influenced by several factors, including the body's own production of prostaglandins and nitric oxide. However, when we blocked these mechanisms or inhibited the potassium ATP (K+ ATP) channels, the protective effect appeared to diminish, indicating these pathways play a crucial role in its effectiveness.
Overall, this research provides promising evidence that Quebrachitol could help combat gastric damage from various substances. Its benefits seem to stem from its ability to promote the release of natural protective substances in our body.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
8
Supports healing process
Although my Bullmastiff has lymphoma, he experiences no pain. I've been giving him this product for about a year to assist with healing his occasional skin ulcers on his feet, and increasing the dosage has proven effective. I believe this product has significantly contributed to his well-being and survival despite his diagnosis.
Read More
